BRIEF published on 08/14/2025 at 07:05, 7 months 12 days ago Relief Therapeutics publie son rapport semestriel 2025 THÉRAPEUTIQUE DE SECOURS RLF-TD011 RLF-OD032 Rapport Semestriel 2025 Partenariat NeuroX
BRIEF published on 08/14/2025 at 07:05, 7 months 12 days ago Relief Therapeutics Releases 2025 Half-Year Report Relief Therapeutics RLF-TD011 RLF-OD032 2025 Half-Year Report NeuroX Partnership
PRESS RELEASE published on 08/14/2025 at 07:00, 7 months 12 days ago Relief Therapeutics Publishes 2025 Half-Year Report Relief Therapeutics published its 2025 half-year report, highlighting progress in pipeline candidates for rare diseases and financial status. Corporate update includes advances in wound care and liquid formulation for phenylketonuria Financial Status Relief Therapeutics Rare Diseases 2025 Half-Year Report Pipeline Candidates
BRIEF published on 08/11/2025 at 07:05, 7 months 15 days ago Publication du rapport semestriel 2025 de Relief Therapeutics THÉRAPEUTIQUE DE SECOURS Traitements Innovants Genève Société Biopharmaceutique Rapport Semestriel 2025
BRIEF published on 08/11/2025 at 07:05, 7 months 15 days ago Relief Therapeutics Advances 2025 Half-Year Report Publication Biopharmaceutical Company Relief Therapeutics Innovative Treatments Geneva Half-Year Report 2025
PRESS RELEASE published on 08/11/2025 at 07:00, 7 months 15 days ago Relief Therapeutics Advances Publication of 2025 Half-Year Report Relief Therapeutics advances publication of its 2025 half-year report from August 27 to August 14, 2025, indicating completion ahead of schedule. Company to provide shareholder update and financial statements Biopharmaceutical Relief Therapeutics Publication Innovative Treatment Options 2025 Half-Year Report
BRIEF published on 07/29/2025 at 07:05, 7 months 28 days ago Relief Therapeutics et NeuroX fusionnent, développant ainsi leur technologie de santé basée sur l'IA SIX Swiss Exchange Fusions Et Acquisitions Maladies Neurologiques MindMaze Technologie De La Santé Basée Sur L'IA
BRIEF published on 07/29/2025 at 07:05, 7 months 28 days ago Relief Therapeutics and NeuroX to Merge, Expanding AI Health Tech SIX Swiss Exchange Mergers & Acquisitions Neurological Diseases AI Health Tech MindMaze
PRESS RELEASE published on 07/29/2025 at 07:00, 7 months 28 days ago Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze Relief Therapeutics to merge with NeuroX, successor to MindMaze, creating a SIX-listed, AI-driven health tech company. Transaction expected to close in Q4 2025 Business Combination Relief Therapeutics MindMaze NeuroX AI-driven Health Tech
BRIEF published on 06/20/2025 at 07:05, 9 months 6 days ago Relief Therapeutics fait face à un revers de la FDA concernant la désignation QIDP du RLF-TD011 RLF-TD011 Médicament Orphelin Réponse De La FDA Epidermolyse Bulleuse Désignation QIDP
Published on 03/26/2026 at 23:00, 3 hours 3 minutes ago FutureGen Industries Announces Closing of Debt Settlement
Published on 03/26/2026 at 22:05, 3 hours 58 minutes ago BlackBerry to Announce Fourth Quarter and Fiscal Year 2026 Results on April 9, 2026
Published on 03/26/2026 at 22:00, 4 hours 3 minutes ago Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project
Published on 03/26/2026 at 22:00, 4 hours 3 minutes ago Green Bridge Metals Reports Visible Copper Sulfide Mineralization in Initial 2026 Titac Drilling, Duluth Complex Minnesota
Published on 03/26/2026 at 21:00, 5 hours 3 minutes ago Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity
Published on 03/26/2026 at 20:48, 5 hours 15 minutes ago Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 6 hours 43 minutes ago Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:09, 6 hours 54 minutes ago 2CRSi SA: Résultats 1er Semestre 2025/26 : Chiffre d'Affaires 204,7 M€ (x9,8) EBITDA de 9,6 M€ (x4,6)
Published on 03/26/2026 at 19:09, 6 hours 54 minutes ago 2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)
Published on 03/26/2026 at 18:17, 7 hours 46 minutes ago Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 7 hours 46 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 8 hours 3 minutes ago Arrêté des comptes au 31 décembre 2025 et perspectives 2026
Published on 03/26/2026 at 18:00, 8 hours 3 minutes ago LABORATOIRES EUROMEDIS - Fin du contrat de liquidité
